Culley Brian M Insider Trades

Insider Trading History

Track insider trading activity for Culley Brian M. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $307k 255,516 shares
Last Trade
Mar 12, 2026 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$24.5k 15,000 shares
$1.63
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $3.9M 3,250,000 shares
Last Trade
Mar 05, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.98M 3,250,000 shares
$1.84
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $289k 240,516 shares
Last Trade
Feb 11, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$23.2k 12,869 shares
$1.80
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $0 0 shares
Last Trade
Feb 11, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$56.3k 31,250 shares
$1.80
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $304k 253,385 shares
Last Trade
Feb 11, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$56.3k 31,250 shares
$1.80
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $267k 222,469 shares
Last Trade
Dec 19, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$15k 8,925 shares
$1.68
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $267k 222,135 shares
Last Trade
Dec 19, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$561 334 shares
$1.68
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $2.76M 2,300,000 shares
Last Trade
Mar 10, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.22M 2,300,000 shares
$0.53
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $37.5k 31,250 shares
Last Trade
Feb 11, 2025 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$20.4k 31,249 shares
$0.65
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $256k 213,544 shares
Last Trade
Feb 11, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$8.16k 12,547 shares
$0.65
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $271k 226,091 shares
Last Trade
Feb 11, 2025 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$20.4k 31,249 shares
$0.65
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $234k 194,842 shares
Last Trade
Nov 21, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$24k 40,000 shares
$0.60
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $186k 154,842 shares
Last Trade
May 24, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$10.5k 10,000 shares
$1.05
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $2.28M 1,900,000 shares
Last Trade
Mar 07, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.15M 1,900,000 shares
$1.13
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $189k 157,648 shares
Last Trade
Feb 11, 2024 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$33.7k 31,249 shares
$1.08
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $75k 62,499 shares
Last Trade
Feb 11, 2024 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$33.7k 31,249 shares
$1.08
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $174k 144,842 shares
Last Trade
Feb 11, 2024 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$13.8k 12,806 shares
$1.08
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $2.28M 1,900,000 shares
Last Trade
Mar 09, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.77M 1,900,000 shares
$1.46
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $112k 93,748 shares
Last Trade
Feb 11, 2023 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$42.2k 31,249 shares
$1.35
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
President And CEO
Holding Value $152k 126,399 shares
Last Trade
Feb 11, 2023 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$17.2k 12,744 shares
$1.35
$1.20

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up